-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $280

Benzinga·07/09/2026 12:28:30
Listen to the news
JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $260 to $280.